



**Health Research  
Authority**

**London - Surrey Borders Research Ethics Committee**

Equinox House  
City Link  
Nottingham  
NG2 4LA

**Please note: This is the  
favourable opinion of the REC  
only and does not allow the  
amendment to be implemented  
at NHS sites in England until  
the outcome of the HRA  
assessment has been  
confirmed.**

12 January 2024

Prof Anthony Gordon  
UK Chief Investigator  
Imperial College London  
11th floor Intensive Care Unit  
Charing Cross Hospital  
Fulham Palace Road  
w6 8rf

Dear Prof Gordon

<b>Study title:</b>	<b>Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia</b>
<b>REC reference:</b>	<b>18/LO/0660</b>
<b>EudraCT number:</b>	<b>2015-002340-14</b>
<b>Amendment number:</b>	<b>AM040</b>
<b>Amendment date:</b>	<b>17 November 2023</b>
<b>IRAS project ID:</b>	<b>237150</b>

The above amendment was reviewed by the Sub-Committee in correspondence.

**Ethical opinion**

The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on the basis described in the notice of amendment form and supporting documentation.

**Approved documents**

The documents reviewed and approved at the meeting were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Completed Amendment Tool [REMAP-CAP AM040 Amendment_Tool_v1_6_LOCKED]	1.6	17 November 2023
Cover Letter [REMAP-CAP AM040 cover letter 22.12.2023]	N/A	22 December 2023
Other [AM040_MhraProductsForm_snapshot]	N/A	22 December 2023
Other [REMAP-CAP letter to sites - Anticoagulation and Antiplatelet Domain - 30 November 2023]	N/A	30 November 2023
Other [REMAP-CAP letter to sites - Corticosteroid Domain_06 December 2023]	N/A	06 December 2023
Participant consent form [REMAP-CAP_Tel v2.0 2023.11.16_Clean]	2.0	16 November 2023
Participant consent form [REMAP-CAP_Tel v2.0 2023.11.16_Tracked]	2.0	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_PerLR Sum_ICF v1.4_2023.11.16_Tracked]	1.4	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_PerLR Sum_ICF v1.4_2023.11.16_Clean]	1.4	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_PerLIS_ICF v1.16_2023.11.16_Tracked]	1.16	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_PerLIS_ICF v1.16_2023.11.16_Clean]	1.16	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_YoungChild_PIS_ICF v1.3 2023.12.13_Tracked]	1.3	13 December 2023
Participant information sheet (PIS) [REMAP-CAP_YoungChild_PIS_ICF v1.3 2023.12.13_Clean]	1.3	13 December 2023
Participant information sheet (PIS) [REMAP-CAP_ProLR Sum_ICF v1.8_2023.11.16_Tracked]	1.8	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_ProLR Sum_ICF v1.8_2023.11.16_Clean]	1.8	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_PIS_ICF v1.16_2023.11.16_Tracked]	1.16	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_PIS_ICF v1.16_2023.11.16_Clean]	1.16	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_Child_16-17_PIS_ICF v1.2 2023.11.16_Tracked]	1.2	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_Child_16-17_PIS_ICF v1.2 2023.11.16_Clean]	1.2	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_Child_10-15_PIS_ICF v1.4 2023.11.16_tracked]	1.4	16 November 2023
Participant information sheet (PIS) [REMAP-CAP_Child_10-15_PIS_ICF v1.4 2023.11.16_Clean]	1.4	16 November 2023
Pharmacy Manual [REMAP-CAP pharmacy guide - Version 4 - 26 October 2023]	4.0	26 October 2023
Research protocol or project proposal [REMAP-CAP Immune Modulation Influenza DSA - V1.0 Adult + Paediatric patients - 29 September 2023]	1.0	29 September 2023
Research protocol or project proposal [REMAP-CAP Immune Modulation Influenza DSA - V1.1 Adult patients only - 29 September 2023]	1.1	29 September 2023
Summary of product characteristics (SmPC) [RoActemra 20mg/ml Concentrate for Solution for Infusion - Summary of Product Characteristics (SmPC) - print friendly - (emc)]	N/A	22 November 2022
Summary of product characteristics (SmPC) [Olumiant 2 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)]	N/A	29 September 2023

## Membership of the Committee

The members of the Committee who took part in the review are listed on the attached sheet.

### **Working with NHS Care Organisations**

Sponsors should ensure that they notify the R&D office for the relevant NHS care organisation of this amendment in line with the terms detailed in the categorisation email issued by the lead nation for the study.

### **Amendments related to COVID-19**

We will update your research summary for the above study on the research summaries section of our website. During this public health emergency, it is vital that everyone can promptly identify all relevant research related to COVID-19 that is taking place globally. If you have not already done so, please register your study on a public registry as soon as possible and provide the HRA with the registration detail, which will be posted alongside other information relating to your project.

### **Statement of compliance**

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

### **HRA Learning**

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities— see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

<b>IRAS Project ID - 237150:</b>
----------------------------------

<b>Please quote this number on all correspondence</b>
---

Yours sincerely



pp.

**Dr Mike Philpot**  
**Chair**

E-mail: [surreyborders.rec@hra.nhs.uk](mailto:surreyborders.rec@hra.nhs.uk)

*Enclosures:*

*List of names and professions of members who took part in the review*

Copy to:

*Dr Farah Al-Beidh, Imperial College London*

**London - Surrey Borders Research Ethics Committee**

**Attendance at Sub-Committee of the REC meeting on 11 January 2024**

**Committee Members:**

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Mr. Hakam Abbass	Clinical Research Nurse	Yes	
Dr Mike Philpot	Consultant Psychiatrist (Retired)	Yes	